Minimally Invasive Thoracoscopic Technique for LV Lead Implantation in CRT Patients

A. Droghetti, S. Branzoli, P. Moggio, G. Belotti, S. Valsecchi, A. Coser, F. Guarracini, S. Quintarelli, C. Pederzolli, A. Graffigna, R. Bonmassari, C. Pomarolli, G. Molon, Maria Caterina Bottoli, M. Centonze, M. Campari, M. Marini
{"title":"Minimally Invasive Thoracoscopic Technique for LV Lead Implantation in CRT Patients","authors":"A. Droghetti, S. Branzoli, P. Moggio, G. Belotti, S. Valsecchi, A. Coser, F. Guarracini, S. Quintarelli, C. Pederzolli, A. Graffigna, R. Bonmassari, C. Pomarolli, G. Molon, Maria Caterina Bottoli, M. Centonze, M. Campari, M. Marini","doi":"10.4172/2155-9880.1000575","DOIUrl":null,"url":null,"abstract":"Background: Epicardial placement of the left ventricular (LV) lead is an alternative approach to the standard cardiac resynchronization therapy (CRT) procedure. In our center we developed a minimally invasive thoracoscopic technique. We reviewed our experience to evaluate the long-term safety and effectiveness of the technique. Methods: The procedure is performed under general anesthesia with oro-tracheal intubation and right-sided ventilation, and requires 3 thoracoscopic ports (two 5-mm and one 15-mm). We analyzed 94 consecutive patients referred to our center for epicardial LV lead implantation. Results: Five patients were excluded because of concomitant conditions precluding surgery or lack of indication for CRT. The remaining 89 patients underwent the procedure. Of these, 57 had undergone previous unsuccessful LV lead implantation (Group 1). In the remaining 32 patients, effective CRT was discontinued owing to LV lead dislodgment (Group 2). LV lead implantation was successful in all patients (median pacing threshold 0.8V, IQR: 0.6-1.2, at 0.5 ms, no phrenic nerve stimulation) and CRT was successfully established in all but one patient. No complications were reported, except for 2 cases of transitory peri-electrode bleeding and 3 cases of ventricular fibrillation induced during the procedure (no sequelae). The median procedure time was 75 min (IQR: 55-95). During a median follow-up of 24 [IQR: 13-39] months, 21 patients died and 4 additional device-related complications were reported (comparable rates between groups). Conclusions: Our thoracoscopic approach proved to be safe and effective. It is a viable alternative to the standard transvenous approach in the case of failed de novo implantation and in those patients who positively respond to CRT but experience LV lead dislodgment.","PeriodicalId":15504,"journal":{"name":"Journal of Clinical and Experimental Cardiology","volume":"194 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9880.1000575","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Background: Epicardial placement of the left ventricular (LV) lead is an alternative approach to the standard cardiac resynchronization therapy (CRT) procedure. In our center we developed a minimally invasive thoracoscopic technique. We reviewed our experience to evaluate the long-term safety and effectiveness of the technique. Methods: The procedure is performed under general anesthesia with oro-tracheal intubation and right-sided ventilation, and requires 3 thoracoscopic ports (two 5-mm and one 15-mm). We analyzed 94 consecutive patients referred to our center for epicardial LV lead implantation. Results: Five patients were excluded because of concomitant conditions precluding surgery or lack of indication for CRT. The remaining 89 patients underwent the procedure. Of these, 57 had undergone previous unsuccessful LV lead implantation (Group 1). In the remaining 32 patients, effective CRT was discontinued owing to LV lead dislodgment (Group 2). LV lead implantation was successful in all patients (median pacing threshold 0.8V, IQR: 0.6-1.2, at 0.5 ms, no phrenic nerve stimulation) and CRT was successfully established in all but one patient. No complications were reported, except for 2 cases of transitory peri-electrode bleeding and 3 cases of ventricular fibrillation induced during the procedure (no sequelae). The median procedure time was 75 min (IQR: 55-95). During a median follow-up of 24 [IQR: 13-39] months, 21 patients died and 4 additional device-related complications were reported (comparable rates between groups). Conclusions: Our thoracoscopic approach proved to be safe and effective. It is a viable alternative to the standard transvenous approach in the case of failed de novo implantation and in those patients who positively respond to CRT but experience LV lead dislodgment.
微创胸腔镜技术在CRT患者左室铅植入中的应用
背景:心外膜放置左心室(LV)导联是标准心脏再同步化治疗(CRT)程序的另一种方法。在我们中心我们开发了一种微创胸腔镜技术。我们回顾了我们的经验,以评估该技术的长期安全性和有效性。方法全麻下经口气管插管,右侧通气,需要3个胸腔镜口(2个5mm, 1个15mm)。我们分析了94例到本中心进行心外膜左室导联植入的患者。结果:5例患者因伴有妨碍手术或缺乏CRT指征而被排除。其余89名患者接受了手术。其中57例患者既往行过不成功的左室导联植入(第1组)。其余32例患者因左室导联脱位而终止了有效的CRT(第2组)。所有患者均成功植入左室导联(中位起搏阈值0.8V, IQR: 0.6-1.2, 0.5 ms,无膈神经刺激),除1例患者外,其余患者均成功建立了CRT。除2例暂时性电极周围出血和3例术中诱发心室颤动(无后遗症)外,无其他并发症。中位手术时间为75分钟(IQR: 55-95)。在中位随访24 [IQR: 13-39]个月期间,21例患者死亡,另有4例器械相关并发症报告(组间发生率可比)。结论:胸腔镜入路安全有效。对于重新植入失败的患者和对CRT有积极反应但经历左室导联脱位的患者,它是标准经静脉入路的可行替代方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信